Psychedelic treatments are being positioned within modern clinical care through careful diagnosis, structured support, specialist oversight, and evidence-based indications

Psychedelic treatments are being integrated into modern clinical care as adjuncts for carefully selected patients rather than as stand-alone cures. Clinical use centers on diagnosis, screening, preparation, supervised dosing, and follow-up integration, with the strongest attention on treatment-resistant mental health conditions and specialist-led settings. Psilocybin, MDMA, and ketamine sit at different stages of evidence, regulation, and adoption. Their place in care depends on matching a substance to a specific indication, weighing contraindications such as psychosis risk or medical instability, and embedding treatment within psychotherapy or broader psychiatric management. Modern healthcare systems matter because access, safety, clinician training, and reimbursement will shape whether these interventions remain boutique services or become durable parts of evidence-based medicine. The core question is not whether psychedelics are universally transformative, but where they offer clear benefit within existing standards of care.